Home
Report Store
Hereditary Angioedema - Epidemiology Forecast to 2030

Hereditary Angioedema - Epidemiology Forecast to 2030

Published Date:

Jan 2020

Pages:

100

Delivery Time:

5-7 Business Days

Region:

United States, EU5, Japan,

Hereditary Angioedema Epidemiology Forecast

DelveInsight's 'Hereditary Angioedema - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Hereditary Angioedema epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2017-2030

Hereditary Angioedema Understanding

The DelveInsight Hereditary Angioedema epidemiology report gives a thorough understanding of the Hereditary Angioedema by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Hereditary Angioedema in the US, Europe, and Japan. The report covers the detailed information of the Hereditary Angioedema epidemiology scenario in seven major countries (US, EU5, and Japan).

Hereditary Angioedema Epidemiology Perspective by DelveInsight

The Hereditary Angioedema epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Hereditary Angioedema epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Hereditary Angioedema epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Hereditary Angioedema Detailed Epidemiology Segmentation

The Hereditary Angioedema epidemiology covered in the report provides historical as well as forecasted Hereditary Angioedema epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Hereditary Angioedema report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

The Hereditary Angioedema report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
The Hereditary Angioedema Epidemiology Report and Model provide an overview of the risk factors and global trends of Hereditary Angioedema in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
The report provides insight about the historical and forecasted patient pool of Hereditary Angioedema in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
The report assesses the disease risk and burden and highlights the unmet needs of Hereditary Angioedema
The report provides the segmentation of the Hereditary Angioedema epidemiology

Report Highlights

11-Year Forecast of Hereditary Angioedema epidemiology
7MM Coverage
Total Cases of Hereditary Angioedema
Total Cases of Hereditary Angioedema according to segmentation
Diagnosed cases of Hereditary Angioedema

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Hereditary Angioedema ?
What are the key findings pertaining to the Hereditary Angioedema epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
What would be the total number of patients of Hereditary Angioedema across the 7MM during the forecast period (2017-2030)?
Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
What is the disease risk, burden and unmet needs of the Hereditary Angioedema ?
What are the currently available treatments of Hereditary Angioedema ?

Reasons to buy

The Hereditary Angioedema Epidemiology report will allow the user to -
Develop business strategies by understanding the trends shaping and driving the global Hereditary Angioedema market
Quantify patient populations in the global Hereditary Angioedema market to improve product design, pricing, and launch plans
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Hereditary Angioedema therapeutics in each of the markets covered
Understand the magnitude of Hereditary Angioedema population by its epidemiology
The Hereditary Angioedema Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

Patient Segmentation
Disease Risk and Burden
Risk of disease by the segmentation
Factors driving growth in a specific patient population

1. Key Insights

2. Executive Summary of Hereditary Angioedema

3. Hereditary Angioedema : Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Hereditary Angioedema Epidemiology Scenario in the 7MM (2017- 2030)

5.4. United States Epidemiology

5.4.1. Hereditary Angioedema Epidemiology Scenario in the United States (2017- 2030)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.1.1. Hereditary Angioedema Epidemiology Scenario in Germany (2017- 2030)

5.5.2. France Epidemiology

5.5.2.1. Hereditary Angioedema Epidemiology Scenario in France (2017- 2030)

5.5.3. Italy Epidemiology

5.5.3.1. Hereditary Angioedema Epidemiology Scenario in Italy (2017- 2030)

5.5.4. Spain Epidemiology

5.5.4.1. Hereditary Angioedema Epidemiology Scenario in Spain (2017- 2030)

5.5.5. United Kingdom Epidemiology

5.5.5.1. Hereditary Angioedema Epidemiology Scenario in the United Kingdom (2017-2030)

5.6. Japan Epidemiology

5.6.1. Hereditary Angioedema Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. Hereditary Angioedema Treatment and Management

6.2. Hereditary Angioedema Treatment Algorithm

7. KOL Views

8. Unmet Needs

9. Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

*The table of contents is not exhaustive; will be provided in the final report

Table 1 Hereditary Angioedema Epidemiology in 7MM (2017-2030)

Table 2 Hereditary Angioedema Diagnosed and Treatable Cases in 7MM (2017-2030)

Table 3 Hereditary Angioedema Epidemiology in the United States (2017-2030)

Table 4 Hereditary Angioedema Diagnosed and Treatable Cases in the United States (2017-2030)

Table 5 Hereditary Angioedema Epidemiology in Germany (2017-2030)

Table 6 Hereditary Angioedema Diagnosed and Treatable Cases in Germany (2017-2030)

Table 7 Hereditary Angioedema Epidemiology in France (2017-2030)

Table 8 Hereditary Angioedema Diagnosed and Treatable Cases in France (2017-2030)

Table 9 Hereditary Angioedema Epidemiology in Italy (2017-2030)

Table 10 Hereditary Angioedema Diagnosed and Treatable Cases in Italy (2017-2030)

Table 11 Hereditary Angioedema Epidemiology in Spain (2017-2030)

Table 12 Hereditary Angioedema Diagnosed and Treatable Cases in Spain (2017-2030)

Table 13 Hereditary Angioedema Epidemiology in the United Kingdom (2017-2030)

Table 14 Hereditary Angioedema Diagnosed and Treatable Cases in the United Kingdom (2017-2030)

Table 15 Hereditary Angioedema Epidemiology in Japan (2017-2030)

Table 16 Hereditary Angioedema Diagnosed and Treatable Cases in Japan (2017-2030)

Figure 1 Hereditary Angioedema Epidemiology in 7MM (2017-2030)

Figure 2 Hereditary Angioedema Diagnosed and Treatable Cases in 7MM (2017-2030)

Figure 3 Hereditary Angioedema Epidemiology in the United States (2017-2030)

Figure 4 Hereditary Angioedema Diagnosed and Treatable Cases in the United States (2017-2030)

Figure 5 Hereditary Angioedema Epidemiology in Germany (2017-2030)

Figure 6 Hereditary Angioedema Diagnosed and Treatable Cases in Germany (2017-2030)

Figure 7 Hereditary Angioedema Epidemiology in France (2017-2030)

Figure 8 Hereditary Angioedema Diagnosed and Treatable Cases in France (2017-2030)

Figure 9 Hereditary Angioedema Epidemiology in Italy (2017-2030)

Figure 10 Hereditary Angioedema Diagnosed and Treatable Cases in Italy (2017-2030)

Figure 11 Hereditary Angioedema Epidemiology in Spain (2017-2030)

Figure 12 Hereditary Angioedema Diagnosed and Treatable Cases in Spain (2017-2030)

Figure 13 Hereditary Angioedema Epidemiology in the United Kingdom (2017-2030)

Figure 14 Hereditary Angioedema Diagnosed and Treatable Cases in the United Kingdom (2017-2030)

Figure 15 Hereditary Angioedema Epidemiology in Japan (2017-2030)

Figure 16 Hereditary Angioedema Diagnosed and Treatable Cases in Japan (2017-2030)